Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Inmune Bio, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 48 | 52 | +4 |
| Shares | 2.29M | 2.74M | +447.1K (+19.5%) |
| Value | $25.8M | $32.2M | +$6.37M (+24.7%) |
New holders (11)
Institutions that held Inmune Bio, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Goldman Sachs Group Inc | 87,605 | $1.03M | 0.00% |
| HRT Financial LP | 29,898 | $351.0K | 0.00% |
| Marshall Wace, LLP | 26,825 | $315.2K | 0.00% |
| Brevan Howard Capital Management LP | 16,422 | $193.0K | 0.02% |
| Marathon Trading Investment Management LLC | 14,500 | $170.4K | 0.07% |
| Squarepoint Ops LLC | 13,441 | $157.9K | 0.00% |
| Point72 Asia (Singapore) Pte. Ltd. | 13,438 | $157.9K | 0.04% |
| Y-Intercept (Hong Kong) Ltd | 11,059 | $129.9K | 0.01% |
| Cubist Systematic Strategies, LLC | 4,782 | $56.2K | 0.00% |
| Continuum Advisory, LLC | 1,000 | $10.8K | 0.00% |
| Macquarie Group Ltd | 444 | $5 | 0.00% |
Sold out (7)
Institutions that held Inmune Bio, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Quadrant Capital Group LLC | 60,000 | $675.6K |
| 683 Capital Management, LLC | 19,253 | $216.8K |
| Rockefeller Capital Management L.P. | 18,220 | $205.2K |
| ExodusPoint Capital Management, LP | 14,948 | $168.0K |
| JPMorgan Chase & Co | 3,479 | $39.2K |
| Group One Trading, L.P. | 2,375 | $26.7K |
| Simplex Trading, LLC | 2,090 | $23.0K |